Founded in 2007, Celyad s a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as Dartmouth College, and develops those programs from bench to commercial applications. The Company is currently developing clinical programs in immuno-oncology, testing Natural Killer Receptors T-cells (NKR-T cells) for cancer treatment. A unique approach that has the potential to target and destroy a vast majority of tumor types. Celyad is listed on Euronext Brussels, Euronext Paris and on Nasdaq (CYAD). Immuno-Oncology, Cancer, Immnotherapy, Natural Killer Receptors